PETER CHUNG: Open Payments
NPI 1720083694 · SANTA CLARA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,118 in 47 payments from 11 companies in 2025. Trend: 2023 $2,256 · 2024 $1,417 · 2025 $1,118
Food & beverage: $1,118
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 20 | $452 |
| AstraZeneca Pharmaceuticals LP | 8 | $212 |
| GlaxoSmithKline, LLC. | 5 | $124 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $80 |
| IBSA Pharma Inc. | 3 | $64 |
| Lilly USA, LLC | 3 | $58 |
| SANOFI-AVENTIS U.S. LLC | 1 | $34 |
| ABBVIE INC. | 1 | $28 |
| Amgen Inc. | 1 | $26 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $25 |
Products named: Ozempic, FARXIGA, Rybelsus, AREXVY, JARDIANCE, Tirosint, MOUNJARO, Wegovy.
Industry payments across CA — which companies pay providers there.
